Insight in Quinazoline-based HDAC Inhibitors as Anti-cancer Agents

Title:Insight in Quinazoline-based HDAC Inhibitors as Anti-cancer Agents

Volume: 24

Author(s): Elena Martino*, Shruti Thakur, Arun Kumar, Ashok Kumar Yadav, Donatella Boschi, Deepak Kumar and Marco Lolli

Affiliation:

• Department of Science and Drug Technology, University of Turin, via Pietro Giuria 9, 10125, Turin, Italy

Abstract: Cancer remains a primary cause of death globally, and effective treatments are still limited. While chemotherapy has notably enhanced survival rates, it brings about numerous side effects. Consequently, the ongoing challenge persists in developing potent anti-cancer agents with minimal toxicity. The versatile nature of the quinazoline moiety has positioned it as a pivotal component in the development of various antitumor agents, showcasing its promising role in innovative cancer therapeutics. This concise review aims to reveal the potential of quinazolines in creating anticancer medications that target histone deacetylases (HDACs).

Cite this article as:

Martino Elena*, Thakur Shruti, Kumar Arun, Yadav Kumar Ashok, Boschi Donatella, Kumar Deepak and Lolli Marco, Insight in Quinazoline-based HDAC Inhibitors as Anti-cancer Agents, Mini-Reviews in Medicinal Chemistry 2024; 24 () . https://dx.doi.org/10.2174/0113895575303614240527093106